Literature DB >> 8099139

Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood.

N J Tarbell1, R D Gelber, H J Weinstein, P Mauch.   

Abstract

There have been reports of a high incidence of second malignant disorders in survivors of Hodgkin's disease. We studied the cumulative incidence of second tumours in 191 children, who were 16 years or younger at diagnosis, with stage IA-IVB Hodgkin's disease, treated at the Joint Center for Radiation Therapy, Boston, between 1969 and 1988. The 10-year actuarial survival was 89 (SE 2)%. The median follow-up time was 11 (range 3-21) years from diagnosis. 109 children were initially treated with radiotherapy alone, 61 received chemotherapy and radiotherapy, and 21 received chemotherapy alone. Second tumours arose in 15 patients 6-20 years after the diagnosis of Hodgkin's disease. The estimated cumulative incidence of second malignant disorders at 15 years was 12 (4)% overall. 10 of the second tumours arose among 66 female patients, compared with 5 among 125 male patients (cumulative incidence 24 [9] vs 5 [3]%). The relative risk of a second tumour for female compared with male patients was 4.5 (95% CI 1.4-15.1; p = 0.013). For male patients, the observed incidence of second tumours was 18 times that expected for the normal population (95% CI 6-42), whereas for female patients it was 57 times that expected (27-105). 13 of the second malignant disorders were solid tumours, including 4 breast cancers. Thus, the risk of a child treated for Hodgkin's disease developing a second tumour is higher for girls than for boys. The cumulative incidence of second cancers increases from 10 years after treatment. These findings emphasise the importance of continued surveillance in patients treated for Hodgkin's disease.

Entities:  

Mesh:

Year:  1993        PMID: 8099139     DOI: 10.1016/0140-6736(93)90880-p

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  6 in total

Review 1.  Secondary malignancies across the age spectrum.

Authors:  Andrea K Ng; Lisa B Kenney; Ethel S Gilbert; Lois B Travis
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

2.  Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.

Authors:  Alireza Eghtedar; Ildefonso Rodriguez; Hagop Kantarjian; Susan O'Brien; Naval Daver; Guillermo Garcia-Manero; Alessandra Ferrajoli; Tapan Kadia; Sherry Pierce; Jorge Cortes; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2014-11-03

3.  Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries.

Authors:  J H Olsen; S Garwicz; H Hertz; G Jonmundsson; F Langmark; M Lanning; S O Lie; P J Moe; T Møller; R Sankila
Journal:  BMJ       Date:  1993-10-23

4.  Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose.

Authors:  Louis S Constine; Nancy Tarbell; Melissa M Hudson; Cindy Schwartz; Susan G Fisher; Ann G Muhs; Swati K Basu; Larry E Kun; Andrea Ng; Peter Mauch; Ajay Sandhu; Eva Culakova; Gary Lyman; Nancy Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-01       Impact factor: 7.038

5.  Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin's disease.

Authors:  Swati K Basu; Cindy Schwartz; Susan G Fisher; Melissa M Hudson; Nancy Tarbell; Ann Muhs; Karen J Marcus; Nancy Mendenhall; Peter Mauch; Larry E Kun; Louis S Constine
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-01       Impact factor: 7.038

6.  Should cancer survivors fear radiation-induced sarcomas?

Authors:  M Feigen
Journal:  Sarcoma       Date:  1997
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.